Effect of Zinc Carnosine on Intestinal Permeability in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00149149
Recruitment Status : Unknown
Verified September 2005 by Imperial College London.
Recruitment status was:  Recruiting
First Posted : September 8, 2005
Last Update Posted : July 17, 2007
Wexham GI Trust
Information provided by:
Imperial College London

Brief Summary:
Zinc carnosine is a food supplement which is available in the health food shops. The investigators wish to see if it can reduce intestinal swelling in people who take non-steroidal anti-inflammatory (anti-swelling) drugs (NSAIDs).

Condition or disease Intervention/treatment Phase
Healthy Drug: Zinc carnosine Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Use of Zinc Carnosine on Intestinal Permeability in Healthy Volunteers Taking Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Study Start Date : May 2005

Primary Outcome Measures :
  1. Effect of zinc carnosine in reducing the gut damage caused by non-steroidal anti-inflammatory drugs

Secondary Outcome Measures :
  1. Differences in dyspepsia score
  2. Differences in faecal calprotectin

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Aged 18-35 years

Exclusion Criteria:

  • Conditions known to alter intestinal permeability, eg previous bowel surgery, celiac disease
  • Conditions where NSAIDs are contraindicated, eg asthma, renal failure, heart failure
  • Diabetes
  • Any other serious illness

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00149149

Contact: Asif Mahmood, MD 02083838067

United Kingdom
Imperial College Recruiting
London, United Kingdom, W12 0NN
Contact: Asif Mahmood, MD    02083838067   
Sub-Investigator: Asif Mahmood, MRCP         
Principal Investigator: Raymond Playford, FRCP, PhD         
Sponsors and Collaborators
Imperial College London
Wexham GI Trust
Principal Investigator: Raymond Playford, MD, PhD Imperial College London Identifier: NCT00149149     History of Changes
Other Study ID Numbers: 05/Q0408/19
First Posted: September 8, 2005    Key Record Dates
Last Update Posted: July 17, 2007
Last Verified: September 2005

Keywords provided by Imperial College London:
Reduction in NSAID related gut damage

Additional relevant MeSH terms:
Anti-Inflammatory Agents, Non-Steroidal
Trace Elements
Growth Substances
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Antirheumatic Agents
Anti-Ulcer Agents
Gastrointestinal Agents